1-allylcyclopropane-1-sulfonamide | 669008-28-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磺酸及其衍生物
• 英文名称: 1-allylcyclopropane-1-sulfonamide
• 英文别名: 1-allylcyclopropylsulfonamide；1-allylcyclopropanesulfonamide；1-(Prop-2-en-1-yl)cyclopropane-1-sulfonamide；1-prop-2-enylcyclopropane-1-sulfonamide
• CAS: 669008-28-0
• 化学式: C₆H₁₁NO₂S
• mdl: MFCD27927217
• 分子量: 161.225
• InChiKey: JQLQQPTXRBSHPF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.666
• 拓扑面积：
  68.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-allylcyclopropane-1-sulfonamide 、 N-tert-butoxycarbonyl-L-norvaline 在 N,N'-羰基二咪唑 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 以15%的产率得到
  参考文献：
  名称：

  Improved P2 phenylglycine-based hepatitis C virus NS3 protease inhibitors with alkenylic prime-side substituents

  摘要：

  Phenylglycine has proved to be a useful P2 residue in HCV NS3 protease inhibitors. A novel pi-pi-interaction between the phenylglycine and the catalytic H57 residue of the protease is postulated. We hypothesized that the introduction of a vinyl on the phenylglycine might strengthen this pi-pi-interaction. Thus, herein is presented the synthesis and inhibitory potency of a series of acyclic vinylated phenylglycine-based HCV NS3 protease inhibitors. Surprisingly, inhibitors based on both D-and L-phenylglycine were found to be effective inhibitors, with a slight preference for the D-epimers. Furthermore, prime-side alkenylic extension of the C-terminal acylsulfonamide group gave significantly improved inhibitors with potencies in the nanomolar range (similar to 35 nM), potencies which were retained on mutant variants of the protease. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2010.05.027
• 作为产物：
  描述：

  N-tert-butyl-1-allylcyclopropanesulfonamide 在 三氟乙酸 作用下， 以74%的产率得到1-allylcyclopropane-1-sulfonamide
  参考文献：
  名称：

  A Facile Synthesis of 1-Substituted Cyclopropylsulfonamides

  摘要：

  描述了一种实用、便捷且高产的三步合成环丙烷磺酰胺和1-取代环丙烷磺酰胺的方法，起始材料为3-氯丙烷磺酰氯。

  DOI：

  10.1055/s-2006-933130

文献信息

• Hepatitis C virus inhibitors
  申请人：Hewawasam Piyasena

  公开号：US20070010455A1

  公开（公告）日：2007-01-11

  The present disclosure relates to tripeptide compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

  本公开涉及三肽化合物、组合物和治疗丙型肝炎病毒（HCV）感染的方法。还公开了含有这些化合物的药物组合物以及在治疗HCV感染中使用这些化合物的方法。
• Inhibitors of Hepatitis C Virus
  申请人：D'Andrea Stanley

  公开号：US20080107625A1

  公开（公告）日：2008-05-08

  Macrocyclic peptides are disclosed having the general formula: wherein R 3 , R 3 ′, R 4 , R 6 , R′, X, Q and W are described. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

  揭示了具有一般公式的大环肽： 其中描述了R3、R3'、R4、R6、R'、X、Q和W。还公开了包含这些化合物的组合物以及使用这些化合物抑制HCV的方法。
• Substituted cycloalkyl P1' hepatitis C virus inhibitors
  申请人：——

  公开号：US20040077551A1

  公开（公告）日：2004-04-22

  The present invention relates to tripeptide compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. In particular, the present invention provides novel tripeptide analogs, pharmaceutical compositions containing such analogs and methods for using these analogs in the treatment of HCV infection.

  本发明涉及三肽化合物、组合物及治疗丙型肝炎病毒（HCV）感染的方法。特别是，本发明提供了新的三肽类似物、含有这些类似物的药物组合物以及使用这些类似物治疗HCV感染的方法。
• Hepatitis C Virus Inhibitors
  申请人：Sin Ny

  公开号：US20080119461A1

  公开（公告）日：2008-05-22

  Hepatitis C virus inhibitors having the general formula are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

  抑制丙型肝炎病毒的抑制剂具有一般公式。包含这些化合物的组合物以及使用这些化合物抑制HCV的方法也被披露。
• [EN] HEPATITIS C VIRUS INHIBITORS<br/>[FR] INHIBITEURS DU VIRUS DE L'HEPATITE C
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2005051410A1

  公开（公告）日：2005-06-09

  Hepatitis C virus inhibitors are disclosed having the general formula (I) wherein A, R2, R3, R', B and Y are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

  丙型肝炎病毒抑制剂的一般结构式（I）已被披露，其中A、R2、R3、R'、B和Y在描述中有所描述。还披露了包含这些化合物的组合物以及使用这些化合物抑制HCV的方法。